Genistein treatment effects upin human prostate. Genistein treatment effects upin human prostate

Prior studies support the notion that the experimental chemopreventive agent, genistein, inhibits prostate cancer (PCa) cell movement in humans and that this in turn inhibits metastatic spread, thereby preventing PCa-specific death. As many effects have been ascribed to genistein, it has been considered a non-specific agent. However, its effects are concentration-dependent, and the vast majority of studies use concentrations greater than 3 logs above those associated with dietary consumption. Genistein is found in soy, and individuals consuming soy-based diets have blood concentrations of free genistein in the low nanomalar range. Using dosing guided by phase I pharmacokinetic studies in US men, prospective treatment of men on a phase II trial with genistein for one month prior to radical prostatectomy for localized PCa. Here we conducted an unbiased screening for effects of genistein in prostate as well as evaluate changes between normal and cancer cells. Overall design: To evaluate the performance of LCM coupled to linear amplification and array-based gene profiling across multiple patient samples, normal prostate epithelial cells (N) to prostate cancer cells (T) in prostate tissue from individuals who had undergone radical prostatectomy for localized PCa. Evaluation of gene expression in genistein treated (NG) versus untreated control subjects (N), using tissue obtained as part of a prospective pre-prostatectomy trial. These studies focused upon normal prostate epithelial cells. This population of cells is present in a cancer containing gland, representing an at risk population and constitutes an important target cell population for pharmacologic targeting with chemoprevention agents. Three-condition experiment, N vs. T samples and N vs. NG. No biological replicates samples: 14 N, 10 T, and 10 NG. In total 17 slides were used.